Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Radiation Therapy Quality Assurance (RTQA) of Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer in the PROCLAIM Phase 3 Trial.

Brade AM, Wenz F, Koppe F, Lievens Y, San Antonio B, Iscoe NA, Hossain A, Chouaki N, Senan S.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):927-934. doi: 10.1016/j.ijrobp.2018.04.015. Epub 2018 Apr 12.

PMID:
29976505
3.

Trends in hormonal management of prostate cancer: a population-based study in Ontario.

Bondy SJ, Iscoe NA, Rothwell DM, Gort EH, Fleshner NE, Paszat LF, Browman GP.

Med Care. 2001 Apr;39(4):384-96.

PMID:
11329525
4.

Prostate cancer: 10. Palliative care.

Iscoe NA, Bruera E, Choo RC.

CMAJ. 1999 Feb 9;160(3):365-71. No abstract available.

5.
6.

Prostate cancer screening: waiting for Godot.

Iscoe NA.

CMAJ. 1998 Dec 1;159(11):1375-7. Review. No abstract available.

7.

Prostate cancer: 1. The descriptive epidemiology in Canada.

Levy IG, Iscoe NA, Klotz LH.

CMAJ. 1998 Sep 8;159(5):509-13. Review.

8.

Free-standing health care facilities: financial arrangements, quality assurance and a pilot study.

Lavis JN, Lomas J, Anderson GM, Donner A, Iscoe NA, Gold G, Craighead J.

CMAJ. 1998 Feb 10;158(3):359-63. Review.

9.

We may get this horse to water, but will it drink?

Iscoe NA.

CMAJ. 1998 Feb 10;158(3):345-6. No abstract available.

10.

Prostate cancer screening in the midst of controversy: Canadian men's knowledge, beliefs, utilization, and future intentions.

Mercer SL, Goel V, Levy IG, Ashbury FD, Iverson DC, Iscoe NA.

Can J Public Health. 1997 Sep-Oct;88(5):327-32.

PMID:
9401168
11.

Prostate cancer patients' satisfaction with medical information.

Gray RE, Klotz LH, Iscoe NA, Fitch MI, Franssen E, Johnson BJ, Labrecque MM.

Can J Urol. 1997 Jun;4(2 Supp 1):83-87.

PMID:
12735844
12.

Results of a survey of Canadian men with prostate cancer.

Gray RE, Klotz LH, Iscoe NA, Fitch MI, Franssen E, Johnson BJ, Labrecque MM.

Can J Urol. 1997 Feb;4(2):359-365.

PMID:
12735852
13.

Survey of consecutive prostate cancer patients attending the Toronto Sunnybrook Regional Cancer Centre (TSRCC).

Danjoux CE, DeBoer G, Choo RC, Iscoe NA, Morton GC, Young CS, Bjarnason GA, Klotz LH.

Can J Urol. 1996 Nov;3(4):268-276.

PMID:
12741961
14.

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.

Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HK, Verma S, Armitage GR, Zee B, Bennett K.

J Clin Oncol. 1996 Jul;14(7):2083-90.

PMID:
8683240
15.

MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas.

Ramsay JA, From L, Iscoe NA, Kahn HJ.

J Invest Dermatol. 1995 Jul;105(1):22-6.

16.

Extragonadal germ cell tumors. A 14-year Toronto experience.

Goss PE, Schwertfeger L, Blackstein ME, Iscoe NA, Ginsberg RJ, Simpson WJ, Jones DP, Shepherd FA.

Cancer. 1994 Apr 1;73(7):1971-9.

PMID:
8137224
17.

Temporal trends in breast cancer surgery in Ontario: can one randomized trial make a difference?

Iscoe NA, Naylor CD, Williams JI, DeBoer G, Morgan MW, Fehringer G, Holowaty E.

CMAJ. 1994 Apr 1;150(7):1109-15.

18.

Variation in breast cancer surgery in Ontario.

Iscoe NA, Goel V, Wu K, Fehringer G, Holowaty EJ, Naylor CD.

CMAJ. 1994 Feb 1;150(3):345-52.

19.

A phase II study of weekly edatrexate (10-EDAM) in metastatic melanoma. A National Cancer Institute of Canada Clinical Trials Group study.

Verma S, Quirt IC, Eisenhauer EA, Iscoe NA, Young VJ, Bodurtha AJ, Davidson J.

Ann Oncol. 1993 Mar;4(3):254-5.

PMID:
8471559
20.
21.

Observer error in the characterization of hepatic lesions in patients with neoplastic liver disease.

Iscoe NA, McKee JD, Arenson AM, Szalai JP.

J Clin Ultrasound. 1988 Oct;16(8):577-9.

PMID:
3152403
22.

The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma.

Kersey PA, Iscoe NA, Gapski JA, Osoba D, From L, DeBoer G, Quirt IC.

Br J Surg. 1985 Aug;72(8):614-7.

PMID:
4027532

Supplemental Content

Loading ...
Support Center